Основная статистика
| LEI | J5OIVXX3P24RJRW5CK77 |
| CIK | 10456 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Baxter International Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4448 BAXTER INTERNATIONAL INC. (E |
|
| August 5, 2025 |
Exhibit 10.3 August 2, 2025 Mr. Brent Shafer At the address on file with the Company Dear Brent, On behalf of the Board of Directors (the “Board”) of Baxter International Inc. (the “Company”), we are pleased to confirm the terms of your service as Interim Chief Executive Officer and Chair of the Board (“Interim CEO/Chair”), effective as of February 3, 2025 (the “Start Date”), pursuant to this amen |
|
| July 31, 2025 |
BAXTER REPORTS SECOND-QUARTER 2025 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS SECOND-QUARTER 2025 RESULTS •Second-quarter sales from continuing operations of $2.81 billion increased 4% on a reported basis and 1% on an operational basis, in line with the company’s previously issued guidance1,2 •Second-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.24; adjusted diluted EPS from continuing |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2025 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission Fi |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 7, 2025 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission Fil |
|
| July 7, 2025 |
Offer Letter, effective as of July 7, 2025, by and between Andrew Hider and the Company Exhibit 10.1 July 3, 2025 Mr. Andrew Hider Dear Andrew, We are pleased to welcome you to Baxter International Inc. (“Baxter” or the “Company”) and to confirm our verbal offer of employment. This is where your purpose accelerates our mission to Save and Sustain Lives. At Baxter, you will join around 38,000 colleagues, in 100 countries, who share common traits like being reliable, ethical, and carin |
|
| July 7, 2025 |
BAXTER APPOINTS ANDREW HIDER CHIEF EXECUTIVE OFFICER EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER APPOINTS ANDREW HIDER CHIEF EXECUTIVE OFFICER DEERFIELD, Ill., JULY 7, 2025 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. |
|
| June 12, 2025 |
Exhibit 10.1 U.S. $2,200,000,000 AMENDED AND RESTATED FIVE-YEAR CREDIT AGREEMENT Dated as of June 11, 2025 among BAXTER INTERNATIONAL INC. as the Borrower Representative BAXTER HEALTHCARE SA, BAXTER WORLD TRADE SRL, and Each Additional Borrower from Time to Time Party Hereto as Borrowers THE FINANCIAL INSTITUTIONS NAMED HEREIN as Banks JPMORGAN CHASE BANK, N.A. as Administrative Agent BANK OF AMER |
|
| June 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 11, 2025 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission Fi |
|
| June 12, 2025 |
Exhibit 10.2 U.S. $645,000,000 AMENDED AND RESTATED CREDIT AGREEMENT Dated as of June 11, 2025 among BAXTER INTERNATIONAL INC. as Borrower THE FINANCIAL INSTITUTIONS NAMED HEREIN as Banks JPMORGAN CHASE BANK, N.A. as Administrative Agent and CITIBANK, N.A. as Syndication Agent JPMORGAN CHASE BANK, N.A., and CITIBANK, N.A. as Co-Lead Arrangers and Joint Bookrunners TABLE OF CONTENTS ARTICLE I. DEFI |
|
| May 30, 2025 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on June 10, 2025, pursuant to the provisions of Rule 12d2-2 (a). |
|
| May 29, 2025 |
Conflict Minerals Report for the year ended December 31, 2024 Exhibit 1.01 Baxter International Inc. Conflict Minerals Report For The Year Ended December 31, 2024 This Conflict Minerals Report for the year ended December 31, 2024 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (Rule 13p-1). Rule 13p-1 imposes certain reporting obligations on U.S. Securities and Exchange Commission (SEC) registrants whose manufactu |
|
| May 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report BAXTER INTERNATIONAL INC. (Exact name of the registrant as specified in its charter) Delaware 1-4448 36-0781620 (State of other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) One Baxter Parkway, Deerfield, Illinois 60015 (Address o |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2025 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission File |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4448 BAXTER INTERNATIONAL INC. ( |
|
| May 6, 2025 |
Exhibit 10.1 BAXTER INTERNATIONAL INC. AMENDED AND RESTATED 2021 INCENTIVE PLAN PERFORMANCE SHARE UNIT AWARD GRANT NOTICE Baxter International Inc., a Delaware corporation (the “Company”), pursuant to the Baxter International Inc. Amended and Restated 2021 Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”) the number of pe |
|
| May 6, 2025 |
Exhibit 10.3 BAXTER INTERNATIONAL INC. AMENDED AND RESTATED 2021 INCENTIVE PLAN STOCK OPTION AWARD GRANT NOTICE Baxter International Inc., a Delaware corporation (the “Company”), pursuant to the Baxter International Inc. Amended and Restated 2021 Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”) the number of stock option |
|
| May 6, 2025 |
Exhibit 10.2 BAXTER INTERNATIONAL INC. AMENDED AND RESTATED 2021 INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Baxter International Inc., a Delaware corporation (the “Company”), pursuant to the Baxter International Inc. Amended and Restated 2021 Incentive Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (the “Participant”) the number of Res |
|
| May 1, 2025 |
BAXTER REPORTS FIRST-QUARTER 2025 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS FIRST-QUARTER 2025 RESULTS •First-quarter sales from continuing operations of $2.63 billion increased 5% on both a reported and operational basis, exceeding the company’s previously issued guidance1,2 •First-quarter U.S. GAAP3 diluted earnings per share (EPS) from continuing operations of $0.13; adjusted diluted EPS from continuing operations of $0 |
|
| May 1, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 1, 2025 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission File |
|
| March 25, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14 |
|
| March 25, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| March 14, 2025 |
STOCKHOLDER ENGAGEMENT 1 Baxter International Inc. March 2025 SA F E HA R BO R STAT EMENT 2Baxter International This presentation includes forward-looking statements concerning the company’s financial results (including the outlook for first-quarter and full-year 2025) and business development and regulatory activities. These forward-looking statements are based on assumptions about many important |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 14, 2025 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission F |
|
| February 25, 2025 |
As filed with the U.S. Securities and Exchange Commission on February 25, 2025 As filed with the U.S. Securities and Exchange Commission on February 25, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BAXTER INTERNATIONAL INC. (Exact name of registrant as specified in its charter) Delaware 36-0781620 (State or other jurisdiction of incorporation or organiz |
|
| February 25, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Baxter International Inc. |
|
| February 25, 2025 |
EX-25.1 Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 |
|
| February 25, 2025 |
As filed with the U.S. Securities and Exchange Commission on February 25, 2025 POS AM As filed with the U.S. Securities and Exchange Commission on February 25, 2025 Registration No. 333-264528 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BAXTER INTERNATIONAL INC. (Exact name of registrant as specified in its charter) Delaware 36-0781620 (State or othe |
|
| February 21, 2025 |
Amended and Restated Certificate of Incorporation of Baxter International Inc., dated May 7, 2024 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BAXTER INTERNATIONAL INC. Pursuant to Sections 242 and 245 of the General Corporation Law of Delaware Baxter International Inc., a corporation organized and existing under the General Corporation Law of Delaware, does hereby certify as follows: (1) The name of the corporation is Baxter International Inc. The name under which it was o |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4448 Baxter Internation |
|
| February 21, 2025 |
Baxter International Inc. Securities Trading Policy EXHIBIT 19 BAXTER INTERNATIONAL INC. SECURITIES TRADING POLICY EFFECTIVE AS OF NOVEMBER 11, 2024 Policy Overview This Policy is intended to articulate the principles and policies of Baxter International Inc. (including its subsidiaries, referred to hereafter as the “Company”) regarding compliance with federal, state and foreign securities laws and regulations relating to trading in Company and thi |
|
| February 21, 2025 |
Amended and Restated Bylaws of Baxter International Inc., dated November 26, 2024. EXHIBIT 3.2 BYLAWS OF BAXTER INTERNATIONAL INC. (As Amended and Restated on November 27, 2024) ARTICLE I STOCKHOLDERS SECTION 1. PLACE OF MEETINGS. The Board of Directors (the “Board of Directors”) of Baxter International Inc. (the “Corporation”) may designate the place of meeting for any meetings of stockholders, within or without the State of Delaware, or determine that such meeting shall be hel |
|
| February 21, 2025 |
Subsidiaries of Baxter International Inc. EXHIBIT 21 BAXTER INTERNATIONAL INC. The following is a list of subsidiaries of Baxter International Inc. as of December 31, 2024, omitting some subsidiaries which, when considered in the aggregate, would not constitute a significant subsidiary. Where ownership is less than 100% by Baxter International Inc. or a Baxter International Inc. subsidiary, such has been noted by designating the percentag |
|
| February 21, 2025 |
Description of Securities Registered Under Section 12 of the Exchange Act. EXHIBIT 4.2 BAXTER INTERNATIONAL INC. DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 AS OF DECEMBER 31, 2024 The following is a summary description of each class of securities of Baxter International Inc. (the “Company”) that is registered under Section 12 of the Securities and Exchange Act of 1934, as amended, as of December 31, 2024, consisting |
|
| February 20, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 20, 2025 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commissio |
|
| February 20, 2025 |
BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2024 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2024 RESULTS •Fourth-quarter sales from continuing operations of $2.75 billion increased 1% on a reported basis and 2% on a constant currency basis, exceeding the company’s previously issued guidance1 •Fourth-quarter U.S. GAAP2 diluted earnings per share (EPS) (loss) from continuing operations of ($0.95); adjusted dilut |
|
| February 6, 2025 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On August 12, 2024, Baxter International Inc. (the “Company”) entered into an Equity Purchase Agreement (as may be amended, amended and restated or otherwise modified from time to time in accordance with its terms, the “Purchase Agreement”) with certain affiliates of Carlyle Group Inc. (“Carlyle”), pursuant to which the |
|
| February 6, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2025 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36 |
|
| February 3, 2025 |
BAXTER ANNOUNCES CEO RETIREMENT AND APPOINTMENT OF COO Exhibit 99.1 BAXTER ANNOUNCES CEO RETIREMENT AND APPOINTMENT OF COO • José (Joe) E. Almeida to retire as Chair, President and Chief Executive Officer • Lead Independent Director Brent Shafer appointed Chair and Interim CEO • Board has initiated a comprehensive search to select full-time replacement • Heather Knight appointed Chief Operating Officer DEERFIELD, Ill., FEB. 3, 2025 – Baxter Internatio |
|
| February 3, 2025 |
Letter Agreement, dated February 1, 2025, by and between José E. Almeida and the Company Exhibit 10.1 February 1, 2025 José E. Almeida At the Address on File with the Company Dear Joe: This letter (this “Letter”) confirms our mutual understanding regarding the transition of your employment with Baxter International, Inc. (the “Company”). On behalf of the Board of Directors of the Company (the “Board”), I want to thank you for your years of leadership of the Company. Reference is made |
|
| February 3, 2025 |
Exhibit 10.1 AMENDMENT 1 TO THE EQUITY PURCHASE AGREEMENT This AMENDMENT 1 TO THE EQUITY PURCHASE AGREEMENT (this “Amendment”), is entered into as of January 31, 2025, by and among Spruce Bidco I, Inc., a Delaware corporation (“US Bidco I”), Spruce Bidco II, Inc., a Delaware corporation (“US Bidco II”), Spruce Bidco I Limited, an Irish corporation (“Irish Bidco”), and CP Spruce Holdings, S.C.Sp, a |
|
| February 3, 2025 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2025 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission |
|
| February 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2025 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission |
|
| February 3, 2025 |
Letter Agreement, dated February 1, 2025, by and between Brent Shafer and the Company Exhibit 10.2 February 1, 2025 Mr. Brent Shafer At the address on file with the Company Dear Brent, On behalf of the Board of Directors (the “Board”) of Baxter International Inc. (the “Company”), we are pleased to confirm the terms of your service as Interim Chief Executive Officer and Chair of the Board (“Interim CEO/Chair”), effective February 3, 2025 (the “Start Date”). • Duties; Term. As Interi |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 31, 2025 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission |
|
| November 27, 2024 |
Amended and Restated Bylaws of Baxter International Inc. dated November 26, 2024 BYLAWS OF BAXTER INTERNATIONAL INC. (As Amended and Restated on November 26, 2024) ARTICLE I STOCKHOLDERS SECTION 1. PLACE OF MEETINGS. The Board of Directors (the “Board of Directors”) of Baxter International Inc. (the “Corporation”) may designate the place of meeting for any meetings of stockholders, within or without the State of Delaware, or determine that such meeting shall be held by means o |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 26, 2024 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commissio |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 18, 2024 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commissio |
|
| November 13, 2024 |
BAX / Baxter International Inc. / DODGE & COX - SC 13G/A Passive Investment SC 13G/A 1 d897249dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1 )* BAXTER INTERNATIONAL INC. (Name of Issuer) Common Stock (Title of Class of Securities) 071813109 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| November 12, 2024 |
Exhibit 10.3 BAXTER INTERNATIONAL INC. EXECUTIVE SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION INTRODUCTION Baxter International Inc., a Delaware corporation adopts this Executive Severance Plan and Summary Plan Description (the “Plan”), effective as of the Effective Date (as defined below), for the benefit of certain Eligible Employees (as defined below). The purpose of the Plan is to provide assur |
|
| November 12, 2024 |
Exhibit 10.2 BAXTER INTERNATIONAL INC. Non-Employee Director Compensation Plan (As amended and restated effective January 1, 2025) Terms and Conditions 1.Purpose This Non-Employee Director Compensation Plan (the “Plan”) is adopted by the Board of Directors (the “Board”) of Baxter International Inc. (“Baxter”). This Plan is adopted pursuant to the Baxter International Inc. Amended and Restated 2021 |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4448 BAXTER INTERNATIONAL IN |
|
| November 8, 2024 |
BAXTER REPORTS THIRD-QUARTER 2024 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS THIRD-QUARTER 2024 RESULTS •Baxter third-quarter 2024 sales totaled $3.85 billion1 •Third-quarter total Baxter U.S. GAAP2 diluted earnings per share (EPS) were $0.271; adjusted total Baxter diluted EPS were $0.801, exceeding the company’s previously issued guidance •Third-quarter sales from continuing operations of $2.70 billion increased 4% on bot |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2024 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission |
|
| November 7, 2024 |
exhibit991 SUPPLEMENTAL HISTORICAL FINANCIAL INFORMATION N o v e m b e r 7 , 2 0 24 1 2 NON-GAAP FINANCIAL MEASURES This presentation contains certain financial measures that are not calculated in accordance with U. |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2024 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 8, 2024 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 29, 2024 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commissi |
|
| September 30, 2024 |
BAXTER PROVIDES UPDATE ON NORTH COVE, N.C., FACILITY AND HURRICANE HELENE RELIEF PLANS FOR COMMUNITY Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER PROVIDES UPDATE ON NORTH COVE, N.C., FACILITY AND HURRICANE HELENE RELIEF PLANS FOR COMMUNITY • Baxter’s North Cove facility affected by flooding and currently closed for production as the company assesses extent of the impact •Company is working closely with FDA, ASPR, HHS, FEMA, Department of Homeland Security and local and state officials •Baxter and th |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 9, 2024 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commissio |
|
| September 9, 2024 |
Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER APPOINTS JEFFREY A. CRAIG TO ITS BOARD Addition of Mr. Craig complements current board expertise with deep financial, broad operational and public company board experience DEERFIELD, Ill., SEPT. 9, 2024 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Jeffrey (Jay) A. Craig, former executive chair and chief |
|
| September 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 3, 2024 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commissio |
|
| August 13, 2024 |
EX-99.2 Baxter Investor Announcement August 13, 2024 Exhibit 99.2 Forward-Looking Statements This presentation includes forward-looking statements concerning the company’s financial results (including select longer-term financial forecasts for Baxter’s remaining business following completion of the pending divestiture of the company’s Kidney Care business), the expected timeframe for completing th |
|
| August 13, 2024 |
EX-99.1 Exhibit 99.1 BAXTER ANNOUNCES DEFINITIVE AGREEMENT TO DIVEST ITS VANTIVE KIDNEY CARE SEGMENT TO CARLYLE FOR $3.8 BILLION • Establishes Vantive as a leading standalone kidney care business backed by Carlyle’s global investment team and resources • Sale follows robust process focused on maximizing stockholder value • Provides increased flexibility to deploy capital toward opportunities to ac |
|
| August 13, 2024 |
Exhibit 2.1 EQUITY PURCHASE AGREEMENT by and among BAXTER INTERNATIONAL INC., SPRUCE BIDCO I INC., SPRUCE BIDCO II INC., SPRUCE BIDCO I LIMITED and CP SPRUCE HOLDINGS, S.C.Sp Dated as of August 12, 2024 TABLE OF CONTENTS Page ARTICLE I PURCHASE AND SALE; CLOSING; CLOSING DELIVERIES Section 1.1 Purchase and Sale 3 Section 1.2 Time and Place of Closing 4 Section 1.3 Deliveries at Closing 4 Section 1 |
|
| August 13, 2024 |
Regulation FD Disclosure, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2024 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4448 BAXTER INTERNATIONAL INC. (E |
|
| August 6, 2024 |
BAXTER REPORTS SECOND-QUARTER 2024 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS SECOND-QUARTER 2024 RESULTS •Second-quarter sales from continuing operations of $3.81 billion increased 3% on a reported basis and 4% on a constant currency basis, exceeding the company’s previously issued guidance and delivering constant currency growth across all segments1 •Second-quarter U.S. GAAP2 diluted earnings per share (EPS) from continuin |
|
| August 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2024 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission F |
|
| July 18, 2024 |
Exhibit 10.1 Execution Version U.S. $2,050,000,000 CREDIT AGREEMENT Dated as of July 17, 2024 among BAXTER INTERNATIONAL INC. as Borrower THE FINANCIAL INSTITUTIONS NAMED HEREIN as Banks JPMORGAN CHASE BANK, N.A. as Administrative Agent JPMORGAN CHASE BANK, N.A., BOFA SECURITIES, INC. and CITIBANK, N.A. as Co-Lead Arrangers and Joint Bookrunners TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 SECTION 1. |
|
| July 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 17, 2024 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission Fi |
|
| May 31, 2024 |
Conflict Minerals Report for the year ended December 31, 202 Exhibit 1.01 Baxter International Inc. Conflict Minerals Report For The Year Ended December 31, 2023 This Conflict Minerals Report for the year ended December 31, 2023 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (Rule 13p-1). Rule 13p-1 imposes certain reporting obligations on Securities and Exchange Commission (SEC) registrants whose manufactured p |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report BAXTER INTERNATIONAL INC. (Exact name of the registrant as specified in its charter) Delaware 1-4448 36-0781620 (State of other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) One Baxter Parkway, Deerfield, Illinois 60015 (Address o |
|
| May 15, 2024 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on May 28, 2024, pursuant to the provisions of Rule 12d2-2 (a). |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2024 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission File |
|
| May 7, 2024 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Baxter International Inc. |
|
| May 7, 2024 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BAXTER INTERNATIONAL INC. Pursuant to Sections 242 and 245 of the General Corporation Law of Delaware Baxter International Inc., a corporation organized and existing under the General Corporation Law of Delaware, does hereby certify as follows: (1) The name of the corporation is Baxter International Inc. The name under which it was o |
|
| May 7, 2024 |
As filed with the Securities and Exchange Commission on May 7, 2024. As filed with the Securities and Exchange Commission on May 7, 2024. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware 36-0781620 (State of Incorporation) (I.R.S. Employer Identification No.) One Ba |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4448 BAXTER INTERNATIONAL INC. ( |
|
| May 2, 2024 |
BAXTER REPORTS FIRST-QUARTER 2024 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS FIRST-QUARTER 2024 RESULTS •First-quarter sales from continuing operations of $3.59 billion increased 2% on a reported basis and 3% on a constant currency basis, exceeding the company’s previously issued guidance1 •First-quarter U.S. GAAP2 diluted earnings per share (EPS) from continuing operations were $0.07 and adjusted diluted EPS from continuin |
|
| May 2, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2024 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission File |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 25, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule |
|
| March 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| March 21, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2024 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission F |
|
| March 21, 2024 |
Exhibit 10.1 FOURTH AMENDMENT FOURTH AMENDMENT, dated as of March 21, 2024 (this “Amendment”), among Baxter International Inc., a Delaware corporation (the “Borrower”), the Banks party hereto and JPMorgan Chase Bank, N.A., as Administrative Agent (in such capacity, the “Administrative Agent”). All capitalized undefined terms used in this Amendment shall have the meanings assigned thereto in the Cr |
|
| March 21, 2024 |
Exhibit 10.2 FOURTH AMENDMENT FOURTH AMENDMENT, dated as of March 21, 2024 (this “Amendment”), among Baxter International Inc., a Delaware corporation (the “Borrower”), the Banks party hereto and JPMorgan Chase Bank, N.A., as Administrative Agent (in such capacity, the “Administrative Agent”). All capitalized undefined terms used in this Amendment shall have the meanings assigned thereto in the Cr |
|
| March 21, 2024 |
Exhibit 10.3 THIRD GUARANTY AMENDMENT THIRD GUARANTY AMENDMENT (this “Amendment”), dated as of March 21, 2024, to the Amended and Restated Guaranty, dated as of October 1, 2021, as amended by that certain Second Amendment, dated as of September 28, 2022 and that certain Second Guaranty Amendment, dated as of March 13, 2023 (as further amended, restated, supplemented or otherwise modified prior to |
|
| March 14, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☑ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 4, 2024 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission Fi |
|
| February 13, 2024 |
BAX / Baxter International Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0413-baxterinternationalin.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Baxter International Inc Title of Class of Securities: Common Stock CUSIP Number: 071813109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box |
|
| February 13, 2024 |
BAX / Baxter International Inc. / DODGE & COX - SC 13G Passive Investment SC 13G 1 d771300dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 0 )* BAXTER INTERNATIONAL INC. (Name of Issuer) Common Stock (Title of Class of Securities) 071813109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 8, 2024 |
Exhibit 10.27 BAXTER INTERNATIONAL INC. DIRECTORS’ DEFERRED COMPENSATION PLAN (Amended and Restated Effective January 31, 2024) TABLE OF CONTENTS ARTICLE I PURPOSE AND EFFECTIVE DATE 1.1 Purpose 1.2 Effective Date ARTICLE II DEFINITIONS 2.1 Account 2.2 Administrator 2.3 Baxter 2.4 Beneficiary 2.5 Board 2.6 Code 2.7 Compensation 2.8 Compensation Committee 2.9 Deferral 2.10 Deferral Election Form 2. |
|
| February 8, 2024 |
BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2023 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2023 RESULTS •Fourth-quarter sales from continuing operations of $3.89 billion increased 4% on a reported basis and 3% on a constant currency basis1 •Fourth-quarter U.S. GAAP diluted earnings per share (EPS) from continuing operations of $0.14 and adjusted diluted EPS from continuing operations of $0.88 •Full-year sales |
|
| February 8, 2024 |
Subsidiaries of Baxter International Inc. EXHIBIT 21 BAXTER INTERNATIONAL INC. The following is a list of subsidiaries of Baxter International Inc. as of December 31, 2023, omitting some subsidiaries which, when considered in the aggregate, would not constitute a significant subsidiary. Where ownership is less than 100% by Baxter International Inc. or a Baxter International Inc. subsidiary, such has been noted by designating the percentag |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4448 Baxter Internation |
|
| February 8, 2024 |
Baxter International Inc. Mandatory Clawback Policy. EXHIBIT 97.1 BAXTER INTERNATIONAL INC. MANDATORY CLAWBACK POLICY I. BACKGROUND Baxter International Inc. (the “Company”) has adopted this policy (as amended and restated, this “Policy”) to provide for the recovery or “clawback” of certain incentive compensation in the event of a Restatement. This Policy is intended to comply with, and will be interpreted to be consistent with, the requirements of |
|
| February 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2024 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission |
|
| February 8, 2024 |
Offer Letter, dated April 22, 2023, by and between the Company and Christopher Toth. Exhibit 10.31 April 22, 2023 Chris Toth Dear Chris, We are pleased to welcome you to Baxter International Inc. (“Baxter” or the “Company”) and to confirm our verbal offer of employment. This is where your purpose accelerates our mission to Save and Sustain Lives. At Baxter, you will join around 60,000 colleagues, in 100 countries, who share common traits like being reliable, ethical, and caring. T |
|
| November 2, 2023 |
BAXTER REPORTS THIRD-QUARTER 2023 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS THIRD-QUARTER 2023 RESULTS •Third-quarter revenue from continuing operations of $3.71 billion increased 3% on a reported basis and 2% on a constant currency basis, ahead of the company’s previously issued guidance1 •Third-quarter U.S. GAAP earnings per share (EPS) from continuing operations of $0.09; adjusted EPS from continuing operations of $0.68 |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4448 BAXTER INTERNATIONAL IN |
|
| November 2, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2023 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission |
|
| October 3, 2023 |
BAXTER APPOINTS JOEL GRADE CHIEF FINANCIAL OFFICER Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER APPOINTS JOEL GRADE CHIEF FINANCIAL OFFICER DEERFIELD, Ill., Oct. 3, 2023 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed Joel Grade as executive vice president and chief financial officer (CFO), reporting to Baxter chairman, president and CEO, José (Joe) E. Almeida, effective Oct. 18, 2023. At that time, B |
|
| October 3, 2023 |
EX-10.1 Exhibit 10.1 September 26, 2023 Joel Grade Dear Joel, We are pleased to welcome you to Baxter International Inc. (“Baxter” or the “Company”) and to confirm our verbal offer of employment. This is where your purpose accelerates our mission to Save and Sustain Lives. At Baxter, you will join around 60,000 colleagues, in 100 countries, who share common traits like being reliable, ethical, and |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 29, 2023 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commissi |
|
| October 2, 2023 |
Regulation FD Disclosure, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 29, 2023 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commissi |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 18, 2023 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission |
|
| August 21, 2023 |
BAXTER ANNOUNCES UPDATES TO ITS BOARD OF DIRECTORS Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER ANNOUNCES UPDATES TO ITS BOARD OF DIRECTORS •Addition of Stephen H. Rusckowski complements and expands current board expertise with deep healthcare industry and public company board experience •Michael Mahoney to resign after nearly eight years of board service DEERFIELD, Ill., AUG. 21, 2023 – Baxter International Inc. (NYSE:BAX), a global medtech leader, |
|
| July 27, 2023 |
BAXTER REPORTS SECOND-QUARTER 2023 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS SECOND-QUARTER 2023 RESULTS •Second-quarter revenues increased 3% on a reported basis and 4% on a constant currency basis, ahead of the company’s previously issued guidance1 •Second-quarter U.S. GAAP earnings (loss) per share (EPS) (including discontinued operations) of ($0.28); adjusted EPS (including discontinued operations) of $0.66 •Second-quar |
|
| July 27, 2023 |
Exhibit 10.2 Change In Control Agreement This Change in Control Agreement (“Agreement”) is entered into by Baxter International Inc. (the “Company”) and Christopher Toth (the “Executive”). Whereas, the Company considers it essential to the best interests of its stockholders to foster the continued employment of key management personnel; and Whereas, the Board recognizes that, as is the case with m |
|
| July 27, 2023 |
Exhibit 10.1 July 25, 2023 Mr. Jose E. Almeida Chairman and CEO Baxter International, Inc. One Baxter Parkway Deerfield, IL 60015 UPDATED TERMS OF EMPLOYMENT Dear Joe, The independent members of the Board of Directors of Baxter International Inc. (the Company) believe your leadership and contributions are essential to achieving the successful transformation the Company is undertaking and want to e |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4448 BAXTER INTERNATIONAL INC. (E |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 27, 2023 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission Fi |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 6, 2023 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission Fil |
|
| July 6, 2023 |
exhibit991 STOCKHOLDER ENGAGEMENT 1 Baxter International Inc. July 2023 Exhibit 99.1 SAF E H AR B O R S TAT E M E N T 2Baxter International This presentation includes forward-looking statements concerning the company’s financial results, business development and regulatory activities (including anticipated benefits and estimated timing) and Baxter’s 2030 Corporate Responsibility Commitment and goa |
|
| June 29, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER APPOINTS WILLIAM AMPOFO TO ITS BOARD Addition of Mr. Ampofo complements and expands current board expertise, reflects focus on continued board refreshment efforts DEERFIELD, Ill., JUNE 29, 2023 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced it has appointed William A. Ampofo II, chair, Supply Chain Operations Council and v |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 29, 2023 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission Fi |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report BAXTER INTERNATIONAL INC. (Exact name of the registrant as specified in its charter) Delaware 1-4448 36-0781620 (State of other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) One Baxter Parkway, Deerfield, Illinois 60015 (Address o |
|
| May 31, 2023 |
Conflict Minerals Report for the year ended December 31, 202 Exhibit 1.01 Baxter International Inc. Conflict Minerals Report For The Year Ended December 31, 2022 This Conflict Minerals Report for the year ended December 31, 2022 is presented to comply with Rule 13p-1 (Rule 13p-1) under the Securities Exchange Act of 1934, as amended (the Exchange Act). Rule 13p-1 imposes certain reporting obligations on Securities and Exchange Commission (SEC) registrants w |
|
| May 9, 2023 |
BAXTER ANNOUNCES CFO TRANSITION Jay Saccaro to depart as CFO; Brian Stevens appointed interim CFO EX-99.2 Exhibit 99.2 FOR IMMEDIATE RELEASE BAXTER ANNOUNCES CFO TRANSITION Jay Saccaro to depart as CFO; Brian Stevens appointed interim CFO DEERFIELD, Ill., MAY 9, 2023 – Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the departure of executive vice president and chief financial officer (CFO) Jay Saccaro. Mr. Saccaro will leave Baxter at the end of May after 21 cum |
|
| May 9, 2023 |
EX-2.1 Exhibit 2.1 EXECUTION VERSION EQUITY PURCHASE AGREEMENT by and among BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE CORPORATION, BAXTER DEUTSCHLAND HOLDING GMBH, GAMBRO DIALYSATOREN GMBH BAMBOO US BIDCO LLC and BLITZ 23-317 GMBH Dated as of May 8, 2023 TABLE OF CONTENTS Page ARTICLE I PURCHASE AND SALE; CLOSING; CLOSING DELIVERIES Section 1.1 Purchase and Sale of Interests 2 Section 1.2 Time |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2023 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission File |
|
| May 9, 2023 |
Amended and Restated Bylaws, dated May 6, 2023 EX-3.1 Exhibit 3.1 BYLAWS OF BAXTER INTERNATIONAL INC. (As Amended and Restated on May 6, 2023) ARTICLE I STOCKHOLDERS SECTION 1. PLACE OF MEETINGS. The Board of Directors may designate the place of meeting for any meetings of stockholders, but if no designation is made the place of meeting shall be the principal executive offices of the Corporation. SECTION 2. ANNUAL MEETINGS; NOTICE OF STOCKHOLD |
|
| May 9, 2023 |
EX-99.1 Exhibit 99.1 Baxter Signs Definitive Agreement to Divest its BioPharma Solutions Business to Advent International and Warburg Pincus for $4.25 Billion Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation Net proceeds planned to be redeployed for debt repayment in accordanc |
|
| May 9, 2023 |
BAX / Baxter International Inc. / MORGAN STANLEY - MS AMENDMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2)* BAXTER INTERNATIONAL INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 071813109 - (CUSIP Number) April 28, 2023 - (Date Of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2023 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission File |
|
| April 27, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 27, 2023 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission F |
|
| April 27, 2023 |
BAXTER REPORTS FIRST-QUARTER 2023 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS FIRST-QUARTER 2023 RESULTS •First-quarter revenue of $3.65 billion decreased 2% on a reported basis and increased 2% on a constant currency basis1 •First-quarter U.S. GAAP earnings per share (EPS) totaled $0.09; Adjusted EPS totaled $0.59 •Baxter expects full-year 2023 sales growth of 1% to 2% on a reported basis and ~1% on a constant currency basi |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4448 BAXTER INTERNATIONAL INC. ( |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7 )* Baxter International Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 071813109 (CUSIP Number) March 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| April 10, 2023 |
BAX / Baxter International Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Baxter International Inc. Title of Class of Securities: Common Stock CUSIP Number: 071813109 Date of Event Which Requires Filing of this Statement: March 31, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| March 23, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14 |
|
| March 23, 2023 |
DEFA14A 1 d424476ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as |
|
| March 13, 2023 |
Exhibit 10.3 Execution Version SECOND GUARANTY AMENDMENT SECOND GUARANTY AMENDMENT (this “Amendment”), dated as of March 13, 2023, to the Amended and Restated Guaranty, dated as of October 1, 2021, as amended by that certain Second Amendment, dated as of September 28, 2022 (as further amended, restated, supplemented or otherwise modified prior to the date hereof, the “Guaranty”), by Baxter Interna |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2023 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission F |
|
| March 13, 2023 |
Exhibit 10.1 Execution Version THIRD AMENDMENT THIRD AMENDMENT, dated as of March 13, 2023 (this “Amendment”), among Baxter International Inc., a Delaware corporation (the “Borrower”), the Banks party hereto and JPMorgan Chase Bank, N.A., as Administrative Agent (in such capacity, the “Administrative Agent”). All capitalized undefined terms used in this Amendment shall have the meanings assigned t |
|
| March 13, 2023 |
Exhibit 10.2 Execution Version THIRD AMENDMENT THIRD AMENDMENT, dated as of March 13, 2023 (this “Amendment”), among Baxter International Inc., a Delaware corporation (the “Borrower”), the Banks party hereto and JPMorgan Chase Bank, N.A., as Administrative Agent (in such capacity, the “Administrative Agent”). All capitalized undefined terms used in this Amendment shall have the meanings assigned t |
|
| February 14, 2023 |
Exhibit 10.1 Baxter International Inc. Executive Officer Cash Severance Policy Baxter International Inc. (the “Company”) will not enter into any new employment agreement or severance agreement with any executive officer or establish any new severance plan or policy covering any executive officer that provides for Cash Severance Benefits (as defined below) exceeding 2.99 times the sum of the execut |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware 1-4448 36-0781620 (State or other jurisdiction of incorporation) (Commissio |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2023 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission |
|
| February 9, 2023 |
BAX / Baxter International Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Baxter International Inc. Title of Class of Securities: Common Stock CUSIP Number: 071813109 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 9, 2023 |
BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2022 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2022 RESULTS •Fourth-quarter sales of $3.9 billion increased 11% on a reported basis, 17% on a constant currency basis and 2% on an operational basis1 •Fourth-quarter U.S. GAAP diluted earnings per share (EPS) of $0.36 and adjusted diluted EPS of $0.88 •Full-year sales of $15.1 billion increased 18% on a reported basis, |
|
| February 9, 2023 |
Subsidiaries of Baxter International Inc. EXHIBIT 21 BAXTER INTERNATIONAL INC. The following is a list of subsidiaries of Baxter International Inc. as of December 31, 2022, omitting some subsidiaries which, when considered in the aggregate, would not constitute a significant subsidiary. Where ownership is less than 100% by Baxter International Inc. or a Baxter International Inc. subsidiary, such has been noted by designating the percentag |
|
| February 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4448 Baxter Internation |
|
| February 9, 2023 |
Exhibit 10.27 BAXTER INTERNATIONAL INC. Non-Employee Director Compensation Plan (As amended and restated effective January 1, 2023) Terms and Conditions 1.Purpose This Non-Employee Director Compensation Plan (the “Plan”) is adopted by the Board of Directors (the “Board”) of Baxter International Inc. (“Baxter”). This Plan is adopted pursuant to the Baxter International Inc. 2021 Incentive Plan (the |
|
| February 6, 2023 |
SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* Baxter International Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 071813109 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 6, 2023 |
Exhibit 99.1 BAXTER ANNOUNCES STRATEGIC ACTIONS TO ENHANCE OPERATIONAL EFFECTIVENESS, ACCELERATE INNOVATION FOR PATIENTS AND DRIVE VALUE FOR SHAREHOLDERS ?Planning to spin off the Renal Care and Acute Therapies global business units into an independent, publicly traded company in the next 12-18 months ?Simplifying operating model and manufacturing footprint to drive strategic clarity, improve oper |
|
| January 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 4, 2023 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4448 BAXTER INTERNATIONAL IN |
|
| October 27, 2022 |
BAXTER REPORTS THIRD-QUARTER 2022 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS THIRD-QUARTER 2022 RESULTS •Third-quarter revenue of $3.8 billion increased 17% on a reported basis, 23% on a constant currency basis and rose slightly on an operational basis1 •Third-quarter U.S. GAAP earnings (loss) per share (EPS) were ($5.83); Adjusted EPS totaled $0.82 •Third-quarter results reflect impairment charges of $3.1 billion related t |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 27, 2022 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission |
|
| September 30, 2022 |
Exhibit 10.1 Execution Version FIRST AMENDMENT FIRST AMENDMENT, dated as of September 28, 2022 (this ?Amendment?), among Baxter International Inc., a Delaware corporation (the ?Borrower?), the Banks party hereto and JPMorgan Chase Bank, N.A., as Administrative Agent (in such capacity, the ?Administrative Agent?). All capitalized undefined terms used in this Amendment shall have the meanings assign |
|
| September 30, 2022 |
Exhibit 10.5 Execution Version SECOND AMENDMENT SECOND AMENDMENT (this ?Amendment?), dated as of September 28, 2022, to the Credit Agreement, dated as of December 20, 2019, as amended by that certain First Amendment, dated as of October 1, 2021 (as further amended, restated, supplemented or otherwise modified prior to the date hereof, the ?Credit Agreement?), among BAXTER HEALTHCARE SA, a corporat |
|
| September 30, 2022 |
Exhibit 10.4 Execution Version SECOND AMENDMENT SECOND AMENDMENT, dated as of September 28, 2022 (this ?Amendment?), among Baxter International Inc., a Delaware corporation (the ?Borrower?), the Banks party hereto and JPMorgan Chase Bank, N.A., as Administrative Agent (in such capacity, the ?Administrative Agent?). All capitalized undefined terms used in this Amendment shall have the meanings assi |
|
| September 30, 2022 |
Exhibit 10.3 Execution Version FIRST AMENDMENT FIRST AMENDMENT, dated as of September 28, 2022 (this ?Amendment?), among Baxter International Inc., a Delaware corporation (the ?Borrower?), the Banks party hereto and JPMorgan Chase Bank, N.A., as Administrative Agent (in such capacity, the ?Administrative Agent?). All capitalized undefined terms used in this Amendment shall have the meanings assign |
|
| September 30, 2022 |
Exhibit 10.2 Execution Version SECOND AMENDMENT SECOND AMENDMENT, dated as of September 28, 2022 (this ?Amendment?), among Baxter International Inc., a Delaware corporation (the ?Borrower?), the Banks party hereto and JPMorgan Chase Bank, N.A., as Administrative Agent (in such capacity, the ?Administrative Agent?). All capitalized undefined terms used in this Amendment shall have the meanings assi |
|
| September 30, 2022 |
Exhibit 99.1 Fall Stockholder Engagement Baxter International Inc. October 2022 Safe Harbor Statement This presentation includes forward-looking statements concerning the company?s financial results, business development and regulatory activities (including the December 2021 acquisition of Hillrom), the anticipated impact of Value Improvement Processes (VIP) and the 2030 company?s corporate respon |
|
| September 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware 1-4448 36-0781620 (State or other jurisdiction of incorporation) (Commissi |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4448 BAXTER INTERNATIONAL INC. (E |
|
| July 28, 2022 |
BAXTER REPORTS SECOND-QUARTER 2022 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS SECOND-QUARTER 2022 RESULTS ?Second-quarter revenue of $3.75 billion increased 21% on a reported basis, 26% on a constant currency basis and 3% on an operational basis1 ?Second-quarter U.S. GAAP earnings per share (EPS) totaled $0.50; Adjusted EPS totaled $0.87 ?Baxter now expects full-year 2022 sales growth to advance in the high teens on a report |
|
| July 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 28, 2022 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission Fi |
|
| May 31, 2022 |
Conflict Minerals Report for the year ended December 31, 2021 Exhibit 1.01 Baxter International Inc. Conflict Minerals Report For The Year Ended December 31, 2021 This Conflict Minerals Report for the year ended December 31, 2021 is presented to comply with Rule 13p-1 (Rule 13p-1) under the Securities Exchange Act of 1934, as amended (the Exchange Act). Rule 13p-1 imposes certain reporting obligations on Securities and Exchange Commission (SEC) registrants w |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM SD Specialized Disclosure Report BAXTER INTERNATIONAL INC. (Exact name of the registrant as specified in its charter) Delaware 1-4448 36-0781620 (State of other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) One Baxter Parkway, Deerfield, Illinois 60015 (Address o |
|
| May 25, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 25, 2022 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission Fil |
|
| May 25, 2022 |
BAXTER HIGHLIGHTS BUSINESS STRATEGIES AND INNOVATION AT 2022 INVESTOR CONFERENCE Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER HIGHLIGHTS BUSINESS STRATEGIES AND INNOVATION AT 2022 INVESTOR CONFERENCE ?Company to share strategy for ongoing growth and innovation aligned with mission to save and sustain lives and vision to transform healthcare ?Recent Hillrom acquisition positions Baxter to accelerate value for patients, clinicians, investors and other stakeholders ?Company announce |
|
| May 12, 2022 |
Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-264529 PROSPECTUS Baxter International Inc. Offers to Exchange Up to $800,000,000 aggregate principal amount of new 0.868% Senior Notes due 2023 registered under the Securities Act of 1933, for any and all outstanding unregistered 0.868% Senior Notes due 2023; Up to $1,400,000,000 aggregate principal amount of new 1.322% Senio |
|
| May 9, 2022 |
[Baxter International Inc. Letterhead] [Baxter International Inc. Letterhead] May 9, 2022 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Re: Baxter International Inc. Registration Statement filed on Form S-3 Filed April 28, 2022 File No. 333-264528 Ladies and Gentlemen: Pursuant to Rule 461 under the S |
|
| May 9, 2022 |
[Baxter International Inc. Letterhead] [Baxter International Inc. Letterhead] May 9, 2022 Via EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Laura Crotty Re: Baxter International Inc. Registration Statement filed on Form S-4 Filed April 28, 2022 File No. 333-264529 Ladies and Gentlemen: Pursuant to Rule 46 |
|
| May 6, 2022 |
[Baxter International Inc. Letterhead] [Baxter International Inc. Letterhead] May 6, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F. Street, N.E. Washington, D.C. 20549 Attention: Chris Edwards Laura Crotty Re: Baxter International Inc. Registration Statement on Form S-4 Filed April 28, 2022 File No. 333-264529 Ladies and Gentlemen: On behalf of Baxter Inter |
|
| May 6, 2022 |
Amended and Restated Certificate of Incorporation of Baxter International Inc. dated May 5, 2022 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION of BAXTER INTERNATIONAL INC. Pursuant to Sections 242 and 245 of the General Corporation Law of Delaware Baxter International Inc., a corporation organized and existing under the General Corporation Law of Delaware, does hereby certify as follows: (1) The name of the corporation is Baxter International Inc. The name under which it was o |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware 1-4448 36-0781620 (State or other jurisdiction of incorporation) (Commission File |
|
| May 6, 2022 |
Amended and Restated Bylaws dated May 5, 2022 EX-3.2 3 d147479dex32.htm EX-3.2 Exhibit 3.2 BYLAWS OF BAXTER INTERNATIONAL INC. (As Amended and Restated on May 5, 2022) ARTICLE I STOCKHOLDERS SECTION 1. PLACE OF MEETINGS. The Board of Directors may designate the place of meeting for any meetings of stockholders, but if no designation is made the place of meeting shall be the principal executive offices of the Corporation. SECTION 2. ANNUAL MEE |
|
| April 28, 2022 |
Form of 2.272% Senior Notes due 2028. Exhibit 4.6 [FORM OF FACE OF NOTE] THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE AND, UNLESS AND UNTI |
|
| April 28, 2022 |
Form of 2.539% Senior Notes due 2032. Exhibit 4.7 [FORM OF FACE OF NOTE] THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE AND, UNLESS AND UNTI |
|
| April 28, 2022 |
Form of Floating Rate Senior Notes due 2024. EX-4.10 9 d328024dex410.htm EX-4.10 Exhibit 4.10 [FORM OF FACE OF NOTE] THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED |
|
| April 28, 2022 |
Offer Letter between Baxter Healthcare (Asia) Pte Ltd and Andrew Frye, dated July 1, 2019 Exhibit 10.4 PRIVATE & CONFIDENTIAL Andrew Frye 10 June 2019 Dear Andrew, Employment Agreement With reference to the recent discussion, Baxter Healthcare (Asia) Pte Ltd (the ?Company?), is pleased to offer you employment under this Employment Agreement (?Agreement?) and as follows: 1.Conditions to Offer: This offer is contingent upon: a)your securing a valid work pass for employment in Singapore; |
|
| April 28, 2022 |
EX-FILING FEES 7 d310531dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table FORM S-3 (Form Type) Baxter International Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Ag |
|
| April 28, 2022 |
As filed with the Securities and Exchange Commission on April 28, 2022 Table of Contents As filed with the Securities and Exchange Commission on April 28, 2022 Registration No. |
|
| April 28, 2022 |
Exhibit 10.2 BAXTER INTERNATIONAL INC. 2021 INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Baxter International Inc., a Delaware corporation (the ?Company?), pursuant to the Baxter International Inc. 2021 Incentive Plan, as may be amended from time to time (the ?Plan?), hereby grants to the holder listed below (the ?Participant?) the number of Restricted Stock Units set forth below (the ? |
|
| April 28, 2022 |
Form of 0.868% Senior Note due 2023. Exhibit 4.3 [FORM OF FACE OF NOTE] THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE AND, UNLESS AND UNTI |
|
| April 28, 2022 |
As filed with the Securities and Exchange Commission on April 28, 2022 Table of Contents As filed with the Securities and Exchange Commission on April 28, 2022 Registration No. |
|
| April 28, 2022 |
Exhibit 10.5 Date: June 10, 2019 To: Andrew Frye RE: Baxter Equity You will continue to be eligible to participate in the Long-Term Incentive (LTI) Program for senior management in accordance with the terms of the LTI program. The next LTI grant is currently scheduled for March 2020. Your equity target will be USD 1,400,000. The LTI Program delivers this value through a mix of 50% stock options an |
|
| April 28, 2022 |
Exhibit 107 Calculation of Filing Fee Table FORM S-4 (Form Type) Baxter International Inc. |
|
| April 28, 2022 |
Form of Letter of Transmittal. Exhibit 99.1 LETTER OF TRANSMITTAL Relating to Baxter Offers to Exchange Up to $800,000,000 Principal Amount Outstanding of Unregistered 0.868% Senior Notes due 2023 (CUSIP Nos.: 071813 CC1, U07181 BB2; ISIN: US071813CC10, USU07181BB21) for a Like Principal Amount of 0.868% Senior Notes due 2023 which have been registered under the Securities Act of 1933 (CUSIP No.: 071813 CE7; ISIN: US071813CE75) |
|
| April 28, 2022 |
BAXTER REPORTS FIRST-QUARTER 2022 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS FIRST-QUARTER 2022 RESULTS ?First-quarter revenue of $3.7 billion increased 26% on a reported basis, 29% on a constant currency basis and 3% on an operational basis1 ?First-quarter U.S. GAAP earnings per share (EPS) totaled $0.14; Adjusted EPS totaled $0.93 ?Baxter expects full-year 2022 sales growth of 23% to 24% on a reported basis, 25% to 26% on |
|
| April 28, 2022 |
Form of Floating Rate Senior Notes due 2023. Exhibit 4.9 [FORM OF FACE OF NOTE] THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE AND, UNLESS AND UNTI |
|
| April 28, 2022 |
Form of 3.132% Senior Notes due 2051. Exhibit 4.8 [FORM OF FACE OF NOTE] THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE AND, UNLESS AND UNTI |
|
| April 28, 2022 |
Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. E |
|
| April 28, 2022 |
Form of Performance Stock Unit Grant Agreement under Baxter International Inc. 2021 Incentive Plan Exhibit 10.1 BAXTER INTERNATIONAL INC. 2021 INCENTIVE PLAN PERFORMANCE SHARE UNIT AWARD GRANT NOTICE Baxter International Inc., a Delaware corporation (the ?Company?), pursuant to the Baxter International Inc. 2021 Incentive Plan, as may be amended from time to time (the ?Plan?), hereby grants to the holder listed below (the ?Participant?) the number of performance share units set forth below (the |
|
| April 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 28, 2022 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission F |
|
| April 28, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On December 13, 2021, Baxter International Inc. (we, our, or us) announced that we completed the previously announced acquisition of Hill-Rom Holdings, Inc. (Hillrom). The unaudited pro forma condensed combined statement of income for the year ended December 31, 2021 gives affect to our results of operations as if the acquis |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4448 BAXTER INTERNATIONAL INC. ( |
|
| April 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 28, 2022 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission F |
|
| April 28, 2022 |
Exhibit 10.3 BAXTER INTERNATIONAL INC. 2021 INCENTIVE PLAN STOCK OPTION AWARD GRANT NOTICE Baxter International Inc., a Delaware corporation (the ?Company?), pursuant to the Baxter International Inc. 2021 Incentive Plan, as may be amended from time to time (the ?Plan?), hereby grants to the holder listed below (the ?Participant?) the number of stock options set forth below (the ?Options?). The Opt |
|
| April 28, 2022 |
Exhibit 10.6 DATE: June 10, 2019 TO: Andrew Frye Addendum to Singapore Employment Contract Dear Andy, Congratulations on your upcoming International Transfer. This letter outlines the provisions relating to your relocation and general transition to Singapore. TRANSFER OF EMPLOYMENT ?All conditions in the Company?s International Transfer Policy apply to your move unless otherwise specified in this |
|
| April 28, 2022 |
EX-4.1 2 d310531dex41.htm EX-4.1 Exhibit 4.1 BAXTER INTERNATIONAL INC. as Issuer and U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of July 29, 2021 RECONCILIATION AND TIE BETWEEN TRUST INDENTURE ACT OF 1939, AS AMENDED, AND INDENTURE CROSS-REFERENCE TABLE1 TIA Section Indenture Section 310(a)(1) 7.09 (a)(2) 7.09 (a)(3) N.A. (a)(4) N.A. (a)(5) 7.09 (b) 7.09, 7.10(d) 311(a) 7.14 (b) 7 |
|
| April 28, 2022 |
Form of 1.322% Senior Notes due 2024. Exhibit 4.4 [FORM OF FACE OF NOTE] THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE AND, UNLESS AND UNTI |
|
| April 28, 2022 |
Form of 1.915% Senior Notes due 2027. Exhibit 4.5 [FORM OF FACE OF NOTE] THIS SECURITY IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE THEREOF. THIS SECURITY IS EXCHANGEABLE FOR SECURITIES REGISTERED IN THE NAME OF A PERSON OTHER THAN THE DEPOSITARY OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE AND, UNLESS AND UNTI |
|
| April 28, 2022 |
Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ? Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter) 91-1821036 I.R.S. E |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.1) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 23, 2022 |
Baxter International Inc. (BAX) Baxter International Inc. (BAX) Shareholder Alert Voluntary submission by John Chevedden, POB 2673, Redondo Beach, CA 90278 Baxter Shareholder since 2010 Vote against management proposals 4 and 5 that have poison pills imbedded Proposal 4 is in regard to shareholders acting by written consent. Proposal 5 is in regard to shareholders calling for a special shareholder meeting. Both topics are for us |
|
| March 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2022 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission F |
|
| March 21, 2022 |
Definitive Proxy Statement on Schedule 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14 |
|
| March 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| March 10, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant CHECK THE APPROPRIATE BOX: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14 |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Baxter International Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 071813109 (CUSIP Number) February 28, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4448 Baxter Internation |
|
| February 23, 2022 |
EX-10.18 2 bax-20211231xexx1018.htm EX-10.18 Exhibit 10.18 BAXTER INTERNATIONAL INC. DIRECTORS’ DEFERRED COMPENSATION PLAN (Amended and Restated Effective November 11, 2021) TABLE OF CONTENTS ARTICLE I PURPOSE AND EFFECTIVE DATE 1 1.1 Purpose 1 1.2 Effective Date 1 ARTICLE II DEFINITIONS 1 2.1 Account 1 2.2 Administrator 1 2.3 Baxter 1 2.4 Beneficiary 1 2.5 Board 1 2.6 Code 1 2.7 Compensation 1 2. |
|
| February 23, 2022 |
EXHIBIT 21 BAXTER INTERNATIONAL INC. The following is a list of subsidiaries of Baxter International Inc. as of December 31, 2021, omitting some subsidiaries which, when considered in the aggregate, would not constitute a significant subsidiary. Where ownership is less than 100% by Baxter International Inc. or a Baxter International Inc. subsidiary, such has been noted by designating the percentag |
|
| February 17, 2022 |
BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE Media Contact Steve Brett, (224) 948-5353 [email protected] Investor Contact Clare Trachtman, (224) 948-3020 BAXTER REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 RESULTS ?Fourth-quarter sales of $3.5 billion increased 10% on a reported basis, 12% on a constant currency basis and 4% on an operational basis1 ?Fourth-quarter U.S. GAAP earnings per share (EPS) of $0.47 an |
|
| February 17, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 17, 2022 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commissio |
|
| February 14, 2022 |
MIRO / Miromatrix Medical Inc. / BAXTER INTERNATIONAL INC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 MIROMATRIX MEDICAL INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) 60471P108 (CUSIP Number) JUNE 23, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 9, 2022 |
BAX / Baxter International Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Baxter International Inc. Title of Class of Securities: Common Stock CUSIP Number: 071813109 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Baxter International Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 071813109 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| December 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 9, 2021 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission |
|
| December 13, 2021 |
BAXTER COMPLETES ACQUISITION OF HILLROM, CREATING ~$15 BILLION GLOBAL MEDTECH LEADER Exhibit 99.1 FOR IMMEDIATE RELEASE Media Contact Lauren Russ, (224) 948-5353 [email protected] Investor Contact Clare Trachtman, (224) 948-3020 BAXTER COMPLETES ACQUISITION OF HILLROM, CREATING ~$15 BILLION GLOBAL MEDTECH LEADER ?Accelerates the company?s vision for transforming healthcare and advancing patient care worldwide ? from the hospital to the home ?Combination creates opportunities for in |
|
| December 13, 2021 |
As filed with the Securities and Exchange Commission on December 13, 2021 As filed with the Securities and Exchange Commission on December 13, 2021 Registration No. |
|
| December 13, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION EX-99.3 5 bax-20211213xex993.htm EX-99.3 Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On September 2, 2021, Baxter International Inc. (we, our, or us) announced that we entered into a definitive agreement to acquire all of the outstanding equity interests of Hill-Rom Holdings, Inc. (Hillrom) for total cash consideration of approximately $10.5 billion. Including the ass |
|
| December 13, 2021 |
Exhibit 99.2 HILL-ROM HOLDINGS, INC. Financial Statements for the years ended September 30, 2021 and 2020 FINANCIAL STATEMENTS INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Financial Statements: Report of Independent Registered Public Accounting Firm 2 Statements of Consolidated Income 4 Statements of Consolidated Comprehensive Income 5 Consolidated Balance Sheets 6 Statements of Consolidated Ca |
|
| December 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 1, 2021 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware 1-4448 36-0781620 (State or other jurisdiction of incorporation) (Commission |
|
| December 2, 2021 |
EX-4.3 4 d270061dex43.htm EX-4.3 Exhibit 4.3 Execution Version BAXTER INTERNATIONAL INC. $800,000,000 0.868% SENIOR NOTES DUE 2023 $1,400,000,000 1.322% SENIOR NOTES DUE 2024 $1,450,000,000 1.915% SENIOR NOTES DUE 2027 $1,250,000,000 2.272% SENIOR NOTES DUE 2028 $1,550,000,000 2.539% SENIOR NOTES DUE 2032 $750,000,000 3.132% SENIOR NOTES DUE 2051 $300,000,000 FLOATING RATE SENIOR NOTES DUE 2023 $3 |
|
| December 2, 2021 |
Exhibit 4.1 Execution Version BAXTER INTERNATIONAL INC. as Issuer and U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of December 1, 2021 RECONCILIATION AND TIE BETWEEN TRUST INDENTURE ACT OF 1939, AS AMENDED, AND INDENTURE CROSS-REFERENCE TABLE1 TIA Section Indenture Section 310(a)(1) 7.09 (a)(2) 7.09 (a)(3) N.A. (a)(4) N.A. (a)(5) 7.09 (b) 7.09, 7.10(d) 311(a) 7.14 (b) 7.14 312(a) 8 |
|
| December 2, 2021 |
Exhibit 4.2 Execution Version 0.868% SENIOR NOTES DUE 2023 1.322% SENIOR NOTES DUE 2024 1.915% SENIOR NOTES DUE 2027 2.272% SENIOR NOTES DUE 2028 2.539% SENIOR NOTES DUE 2032 3.132% SENIOR NOTES DUE 2051 FLOATING RATE SENIOR NOTES DUE 2023 FLOATING RATE SENIOR NOTES DUE 2024 FIRST SUPPLEMENTAL INDENTURE between BAXTER INTERNATIONAL INC., as Issuer and U.S. BANK NATIONAL ASSOCIATION, as Trustee Dat |
|
| November 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2021 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware 1-4448 36-0781620 (State or other jurisdiction of incorporation) (Commissio |
|
| November 30, 2021 |
Exhibit 10.1 November 29, 2021 Dear Giuseppe: Congratulations! We are pleased to offer you the role of Executive Vice President and Chief Operating Officer, reporting to Joe Almeida, Chairman, President and Chief Executive Officer based in Deerfield, IL. This position will be effective Monday, November 29, 2021. TERMS OF EMPLOYMENT The following explains the terms of the offer: ? Your new annual b |
|
| November 17, 2021 |
EX-1.01 2 d436921dex101.htm EX-1.01 Exhibit 1.01 Execution Version BAXTER INTERNATIONAL INC. Debt Securities PURCHASE AGREEMENT November 16, 2021 Baxter International Inc. (the “Company”) One Baxter Parkway Deerfield, IL 60015 Attention: James K. Saccaro Ladies and Gentlemen: On behalf of the several Initial Purchasers named in Schedule I hereto and offer to purchase for their respective accounts, |
|
| November 17, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 16, 2021 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware 1-4448 36-0781620 (State or other jurisdiction of incorporation) (Commissio |
|
| November 15, 2021 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On September 2, 2021, Baxter International Inc. (we or our) announced that we have entered into a definitive agreement to acquire all of the outstanding equity interests of Hill-Rom Holdings, Inc. (Hillrom) for total cash consideration of approximately $10.4 billion. Including the assumption of Hillrom's outstanding debt obl |
|
| November 15, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 15, 2021 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commissio |
|
| October 28, 2021 |
BAXTER REPORTS THIRD-QUARTER 2021 RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE Media Contact Steve Brett, (224) 948-5353 [email protected] Investor Contact Clare Trachtman, (224) 948-3020 BAXTER REPORTS THIRD-QUARTER 2021 RESULTS ?Third-quarter revenue of $3.2 billion increased 9% on a reported basis, 7% on a constant currency basis and 6% on an operational basis1 ?Third-quarter U.S. GAAP earnings per share (EPS) of $0.89 increased 29%; Adju |
|
| October 28, 2021 |
Exhibit 10.4 BAXTER INTERNATIONAL INC. Non-Employee Director Compensation Plan (As amended and restated effective July 1, 2021) Terms and Conditions 1.Purpose This Non-Employee Director Compensation Plan (the ?Plan?) is adopted by the Board of Directors (the ?Board?) of Baxter International Inc. (?Baxter?). This Plan is adopted pursuant to the Baxter International Inc. 2021 Incentive Plan (the ?20 |
|
| October 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 28, 2021 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4448 BAXTER INTERNATIONAL IN |
|
| October 18, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 18, 2021 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission |
|
| October 18, 2021 |
October 2021 Baxter International Inc. Fall Shareholder Engagement 2 This presentation includes forward-looking statements concerning Baxter?s financial results, business development activities, capital structure, cost savings initiatives, R&D pipeline, including results of clinical trials and planned product launches, and outlook for full-year 2021. These forward-looking statements are based on a |
|
| October 4, 2021 |
EX-10.1 2 d218121dex101.htm EX-10.1 Exhibit 10.1 EXECUTION VERSION U.S. $4,000,000,000 CREDIT AGREEMENT Dated as of September 30, 2021 among BAXTER INTERNATIONAL INC. as Borrower THE FINANCIAL INSTITUTIONS NAMED HEREIN as Banks JPMORGAN CHASE BANK, N.A. as Administrative Agent and CITIBANK, N.A. as Syndication Agent JPMORGAN CHASE BANK, N.A., and CITIBANK, N.A. Co-Lead Arrangers and Joint Bookrunn |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware 1-4448 36-0781620 (State or other jurisdiction of incorporation) (Commissi |
|
| October 4, 2021 |
Exhibit 10.2 EXECUTION VERSION U.S. $2,500,000,000 FIVE-YEAR CREDIT AGREEMENT Dated as of September 30, 2021 among BAXTER INTERNATIONAL INC. as Borrower THE FINANCIAL INSTITUTIONS NAMED HEREIN as Banks JPMORGAN CHASE BANK, N.A. as Administrative Agent BANK OF AMERICA, N.A. and CITIBANK, N.A. as Syndication Agents JPMORGAN CHASE BANK, N.A., BofA SECURITIES, INC. and CITIBANK, N.A. Co-Lead Arrangers |
|
| October 4, 2021 |
Exhibit 10.3 EXECUTION VERSION FIRST AMENDMENT FIRST AMENDMENT (this ?Amendment?), dated as of October 1, 2021, to the Credit Agreement, dated as of December 20, 2019, among BAXTER HEALTHCARE SA, a corporation duly organized and existing under the laws of Switzerland (?Baxter Healthcare SA?), BAXTER WORLD TRADE SRL, a private limited liability company duly incorporated under the laws of Belgium, w |
|
| September 2, 2021 |
Exhibit 99.2 Acquisition of September 2, 2021Exhibit 99.2 Acquisition of September 2, 2021 Baxter Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, each as amended, concerning Baxter?s financial |
|
| September 2, 2021 |
Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER entered into by and among HILL-ROM HOLDINGS, INC., BAXTER INTERNATIONAL INC. and BEL AIR SUBSIDIARY, INC. Dated as of September 1, 2021 TABLE OF CONTENTS Page ARTICLE I Definitions; Interpretation and Construction 1.1. Definitions 2 1.2. Other Terms 19 1.3. Interpretation and Construction 19 ARTICLE II Closing; Effective Time; The Merger 2 |
|
| September 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 1, 2021 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commissio |
|
| September 2, 2021 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Media Contacts Baxter: Lauren Russ, (224) 948-5353 [email protected] Hillrom: Howard Karesh, (312) 819-7268 [email protected] Investor Contacts Baxter: Clare Trachtman, (224) 948-3020 [email protected] Hillrom: Mary Kay Ladone, (312) 819-9387 [email protected] BAXTER TO ACQUIRE HILLROM, EXPANDING CONNECTED CARE AND MEDICAL INNOVATION GLOBA |
|
| July 29, 2021 |
EX-25.1 5 d197286dex251.htm EX-25.1 Exhibit 25.1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) U.S. BANK NATIONAL ASSOCIATION (Exact name of Trustee as specified in its charter |
|
| July 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2021 Baxter International Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-4448 36-0781620 (Commission Fi |
|
| July 29, 2021 |
Exhibit 4.1 BAXTER INTERNATIONAL INC. as Issuer and U.S. BANK NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of July 29, 2021 RECONCILIATION AND TIE BETWEEN TRUST INDENTURE ACT OF 1939, AS AMENDED, AND INDENTURE CROSS-REFERENCE TABLE1 TIA Section Indenture Section 310(a)(1) 7.09 (a)(2) 7.09 (a)(3) N.A. (a)(4) N.A. (a)(5) 7.09 (b) 7.09, 7.10(d) 311(a) 7.14 (b) 7.14 312(a) 8.01 (b) 8.02 (c) 8.02 |
|
| July 29, 2021 |
As filed with the Securities and Exchange Commission on July 29, 2021 Table of Contents As filed with the Securities and Exchange Commission on July 29, 2021 Registration No. |
|
| July 29, 2021 |
BAXTER REPORTS SECOND-QUARTER 2021 RESULTS EX-99.1 2 bax-20210630xex991.htm EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Media Contact Steve Brett, (224) 948-5353 [email protected] Investor Contact Clare Trachtman, (224) 948-3020 BAXTER REPORTS SECOND-QUARTER 2021 RESULTS •Second-quarter revenue of $3.1 billion increased 14% on a reported basis, 9% on a constant currency basis and 8% on an operational basis1 •Second-quarter U.S. GAAP earnings |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-4448 BAXTER INTERNATIONAL INC. (E |
|
| July 29, 2021 |
Non-Employee Director Compensation Plan (As Amended and restated effective May 4, 2021) Exhibit 10.1 BAXTER INTERNATIONAL INC. Non-Employee Director Compensation Plan (As amended and restated effective May 4, 2021) Terms and Conditions 1.Purpose This Non-Employee Director Compensation Plan (the ?Plan?) is adopted by the Board of Directors (the ?Board?) of Baxter International Inc. (?Baxter?). This Plan is adopted pursuant to the Baxter International Inc. 2021 Incentive Plan (the ?202 |
